Literature DB >> 10188893

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2.

M J Ligtenberg1, F B Hogervorst, H W Willems, P J Arts, G Brink, S Hageman, E A Bosgoed, E Van der Looij, M A Rookus, P Devilee, E M Vos, G Wigbout, P M Struycken, F H Menko, E J Rutgers, E H Hoefsloot, E C Mariman, H G Brunner, L J Van 't Veer.   

Abstract

For families with a small number of cases of breast and/or ovarian cancer, limited data are available to predict the likelihood of genetic predisposition due to mutations in BRCA1 or BRCA2. In 104 families with three or more affected individuals (average 3.8) seeking counselling at family cancer clinics, mutation analysis was performed in the open reading frame of BRCA1 and BRCA2 by the protein truncation test and mutation-specific assays. In 31 of the 104 families tested, mutations were detected (30%). The majority of these mutations (25) occurred in BRCA1. Mutations were detected in 15 out of 25 families (60%) with both breast and ovarian cancer and in 16 out of 79 families (20%) with exclusively cases of breast cancer. Thus, an ovarian cancer case strongly predicted finding a mutation (P < 0.001). Within the group of small breast-cancer-only families, a bilateral breast cancer case or a unilateral breast cancer case diagnosed before age 40 independently predicted finding a BRCA1 or BRCA2 mutation (P = 0.005 and P = 0.02, respectively). Therefore, even small breast/ovarian cancer families with at least one case of ovarian cancer, bilateral breast cancer, or a case of breast cancer diagnosed before age 40, should be referred for mutation screening.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10188893      PMCID: PMC2362698          DOI: 10.1038/sj.bjc.6690235

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  Population genetics of BRCA1 and BRCA2.

Authors:  C I Szabo; M C King
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

2.  BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.

Authors:  F J Couch; M L DeShano; M A Blackwood; K Calzone; J Stopfer; L Campeau; A Ganguly; T Rebbeck; B L Weber
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

3.  Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer.

Authors:  M Krainer; S Silva-Arrieta; M G FitzGerald; A Shimada; C Ishioka; R Kanamaru; D J MacDonald; H Unsal; D M Finkelstein; A Bowcock; K J Isselbacher; D A Haber
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

4.  Identification of the breast cancer susceptibility gene BRCA2.

Authors:  R Wooster; G Bignell; J Lancaster; S Swift; S Seal; J Mangion; N Collins; S Gregory; C Gumbs; G Micklem
Journal:  Nature       Date:  1995 Dec 21-28       Impact factor: 49.962

5.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.

Authors:  R Wooster; S L Neuhausen; J Mangion; Y Quirk; D Ford; N Collins; K Nguyen; S Seal; T Tran; D Averill
Journal:  Science       Date:  1994-09-30       Impact factor: 47.728

6.  A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families.

Authors:  T Peelen; M van Vliet; A Petrij-Bosch; R Mieremet; C Szabo; A M van den Ouweland; F Hogervorst; R Brohet; M J Ligtenberg; E Teugels; R van der Luijt; A H van der Hout; J J Gille; G Pals; I Jedema; R Olmer; I van Leeuwen; B Newman; M Plandsoen; M van der Est; G Brink; S Hageman; P J Arts; M M Bakker; P Devilee
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

7.  BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients.

Authors:  A Petrij-Bosch; T Peelen; M van Vliet; R van Eijk; R Olmer; M Drüsedau; F B Hogervorst; S Hageman; P J Arts; M J Ligtenberg; H Meijers-Heijboer; J G Klijn; H F Vasen; C J Cornelisse; L J van 't Veer; E Bakker; G J van Ommen; P Devilee
Journal:  Nat Genet       Date:  1997-11       Impact factor: 38.330

8.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

Authors:  Y Miki; J Swensen; D Shattuck-Eidens; P A Futreal; K Harshman; S Tavtigian; Q Liu; C Cochran; L M Bennett; W Ding
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

9.  Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium.

Authors:  D F Easton; D T Bishop; D Ford; G P Crockford
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

10.  Rapid detection of BRCA1 mutations by the protein truncation test.

Authors:  F B Hogervorst; R S Cornelis; M Bout; M van Vliet; J C Oosterwijk; R Olmer; B Bakker; J G Klijn; H F Vasen; H Meijers-Heijboer
Journal:  Nat Genet       Date:  1995-06       Impact factor: 38.330

View more
  7 in total

Review 1.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

2.  De novo recurrent germline mutation of the BRCA2 gene in a patient with early onset breast cancer.

Authors:  R B van der Luijt ; P H van Zon ; R P Jansen; C J van der Sijs-Bos ; C C Wárlám-Rodenhuis; M G Ausems
Journal:  J Med Genet       Date:  2001-02       Impact factor: 6.318

3.  Effect of breast-conserving surgery plus radiotherapy versus mastectomy on breast cancer-specific survival for early-stage contralateral breast cancer.

Authors:  Chao Qian; Yan Liang; Min Yang; Sheng-Nan Bao; Jian-Ling Bai; Yong-Mei Yin; Hao Yu
Journal:  Gland Surg       Date:  2021-10

Review 4.  Key steps for effective breast cancer prevention.

Authors:  Kara L Britt; Jack Cuzick; Kelly-Anne Phillips
Journal:  Nat Rev Cancer       Date:  2020-06-11       Impact factor: 60.716

5.  Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of 'easy to apply' probability models.

Authors:  D Bodmer; M J L Ligtenberg; A H van der Hout; S Gloudemans; K Ansink; J C Oosterwijk; N Hoogerbrugge
Journal:  Br J Cancer       Date:  2006-08-15       Impact factor: 7.640

6.  A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families.

Authors:  P Vahteristo; H Eerola; A Tamminen; C Blomqvist; H Nevanlinna
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

7.  Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients.

Authors:  H Papelard; G H de Bock; R van Eijk; T P Vliet Vlieland; C J Cornelisse; P Devilee; R A Tollenaar
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.